dc.contributorPinzon-Rondon, Angela Maria
dc.contributorGrupo de Investigacion en Salud Publica
dc.creatorMora Rojas, Laura Stephanie
dc.creatorCepeda Salazar, Rodolfo Leonardo
dc.date.accessioned2021-08-31T17:59:41Z
dc.date.accessioned2022-09-22T14:26:38Z
dc.date.available2021-08-31T17:59:41Z
dc.date.available2022-09-22T14:26:38Z
dc.date.created2021-08-31T17:59:41Z
dc.identifierhttps://repository.urosario.edu.co/handle/10336/32332
dc.identifierhttps://doi.org/10.48713/10336_32332
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/3438836
dc.description.abstractCOVID-19, declared a pandemic by the World Health Organization (WHO) on March 11, 2020, has presented to date a confirmed number of 208,470,375 infections worldwide, with a mortality of 2.1%, and 4,877,323 cases in Colombia, with a mortality of 2.5%; After COVID-19 infection, there may be residual symptoms according to various observational studies carried out around the world. This study presents the prevalence of residual symptoms three months after acute infection by COVID-19 at the physical, mental and cognitive level, in relation to the severity of the symptoms and the different sociodemographic, personal and pathological antecedents of a group of patients from Bogotá, between the first and second semesters of 2020. Methodology: A prospective cohort analytical study was carried out, with non-probabilistic convenience sampling in 191 patients with a diagnosis of COVID19 infection, in a group of patients from Bogotá, during the year 2020. A survey was designed online for the collection of information, for the follow-up of patients 3 months after discharge. Sociodemographic and clinical variables were collected. Variables, bivariate and multivariate analyzes are performed. Results: Among the most prevalent physical symptoms are fatigue and sensory alterations in 35.6% of the studied population, followed by dyspnea in 27.2% of the population. As well as mental and cognitive symptoms, 5.8% of cases of anxiety 2.1% of depression and 3.7% of neurological deterioration. The appearance of sensory and motor alterations is statistically related to the ICU requirement and the smoking history, as well as fatigue with smoking history. Finally, when performing a multivariate analysis, some variables associated with sensory impairment, anxiety and cognitive deficit present a normal distribution, with high probability, at a value close to reality. Conclusion: The persistence of symptoms 3 months after COVID-19 infection has a greater impact on neurological and respiratory symptoms, neurological symptoms are statistically significantly associated with the requirement of ICU during care for SARS-CoV infection -2. At the public health level, larger studies are required to continue evaluating the impact of symptoms on people who have suffered from COVID-19
dc.languagespa
dc.publisherUniversidad del Rosario
dc.publisherMaestría en Salud Pública
dc.publisherEscuela de Medicina y Ciencias de la Salud
dc.rightshttp://creativecommons.org/licenses/by-nd/2.5/co/
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rightsAbierto (Texto Completo)
dc.rightsEL AUTOR, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto la obra es de exclusiva autoría y tiene la titularidad sobre la misma. PARGRAFO: En caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la universidad actúa como un tercero de buena fe. EL AUTOR, autoriza a LA UNIVERSIDAD DEL ROSARIO, para que en los términos establecidos en la Ley 23 de 1982, Ley 44 de 1993, Decisión andina 351 de 1993, Decreto 460 de 1995 y demás normas generales sobre la materia, utilice y use la obra objeto de la presente autorización. -------------------------------------- POLITICA DE TRATAMIENTO DE DATOS PERSONALES. Declaro que autorizo previa y de forma informada el tratamiento de mis datos personales por parte de LA UNIVERSIDAD DEL ROSARIO para fines académicos y en aplicación de convenios con terceros o servicios conexos con actividades propias de la academia, con estricto cumplimiento de los principios de ley. Para el correcto ejercicio de mi derecho de habeas data cuento con la cuenta de correo habeasdata@urosario.edu.co, donde previa identificación podré solicitar la consulta, corrección y supresión de mis datos.
dc.rightsAtribución-SinDerivadas 2.5 Colombia
dc.source1. Organización Mundial de la Salud. Cronología de la respuesta de la OMS a la COVID-19. [Online].; 2021 [cited 2021 08 18. Available from: https://www.who.int/es/news/item/29-06-2020-covidtimeline
dc.source2. Organización Mundial de la Salud. WHO Coronavirus (COVID-19) Dashboard. [Online].; 2021 [cited 2021 08 07. Available from: https://covid19.who.int/.
dc.source3. Instituto Nacional de Salud. COVID-19 en Colombia. [Online].; 2021 [cited 2021 08 07. Available from: https://www.ins.gov.co/Noticias/paginas/coronavirus.aspx.
dc.source4. Instituto Nacional de Salud. Distribución geográfica de los linajes de SARS-CoV-2 circulantes en Colombia. [Online].; 2021 [cited 2021 08 06. Available from: https://images.jifo.co/57820265_1627093168914.jpg.
dc.source5. Ministerio de Salud. Colombia confirma la presencia de la variante Delta en el país. [Online].; 2021 [cited 2021 08 10. Available from: https://www.minsalud.gov.co/Paginas/Colombia-confirma-presencia-de-la- variante-Delta-en-el-pais-.aspx.
dc.source6. Organización Mundial de la Salud. Seguimiento de las variantes del SARS-CoV-2. [Online].; 2021 [cited 2021 08 07. Available from: https://www.who.int/es/activities/tracking-SARS-CoV-2-variants.
dc.source7. Oran DP, Topol EJ. The Proportion of SARS-CoV-2 Infections That Are Asymptomatic A Systematic Review. Annals of Internal Medicine. 2021 Jan.
dc.source8. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Apr; 323(13).
dc.source9. Stokes EK, Zambrano LD, Anderson KN, Marder EP, Raz KM, Felix SEB, et al. Coronavirus Disease 2019 Case Surveillance — United States, January 22–May 30, 2020. Morbidity and Mortality Weekly Report. 2020 Jun; 69(24).
dc.source10. Butt A, Nafady-Hego , Chemaitelly , Abou-Samra AB, Al Khal , Coyle P, et al. Outcomes Among Patients with Breakthrough SARS-CoV-2 Infection After Vaccination. International Journal of Infectious Diseases. 2021 Aug.
dc.source11. National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing the long-term effects of COVID-19. 2020 Dec;
dc.source12. Greenhalgh T, Knight, A’Court , Buxton , Husain L. Management of post-acute covid- 19 in primary care. British Medical Journal. 2020 Aug.
dc.source13. van den Borst B, Peters, Brink, Schoon, Bleeker-Rovers, Schers, et al. Comprehensive Health Assessment 3 Months After Recovery From Acute Coronavirus Disease 2019 (COVID-19). Clinical Infectious Diseases. 2020 Nov.
dc.source14. Carfì, Bernabei, Landi. Persistent Symptoms in Patients After Acute COVID-19. JAMA. 2020 Aug; 324(6).
dc.source15. Darcis , Bouquegneau , Maes , Thys , Henket , Labye , et al. Long-term clinical follow- up of patients suffering from moderate-to-severe COVID-19 infection: a monocentric prospective observational cohort study. International Journal of Infectious Diseases. 2021 Jul.
dc.source16. Nielsen KJ, Vestergaard , Schlünssen , Bonde J, Kaspersen , Biering , et al. Day-by-day symptoms following positive and negative PCR tests for SARS-CoV-2 in non- hospitalized healthcare workers: A 90-day follow-up study. International Journal of Infectious Diseases. 2021 May.
dc.source17. Lv , Zhang , Zhu , Xiong , Xiang , Wang , et al. Prevalence and recovery time of olfactory and gustatory dysfunction in hospitalized patients with COVID-19 in Wuhan, China. International Journal of Infectious Diseases. 2020 Sep.
dc.source18. Logue JK, Franko NM, McCulloch DJ, McDonald , Magedson , Wolf CR, et al. Sequelae in Adults at 6 Months After COVID-19 Infection. JAMA. 2021 Feb.
dc.source19. Daugherty SE, Guo , Heath , Dasmariñas MC, Jubilo , Samranvedhya , et al. Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study. BMJ. 2021 Apr.
dc.source20. Del Brutto OH, Wu , Mera RM, Costa AF, Recalde BY, Issa NP. Cognitive decline among individuals with history of mild symptomatic SARS-CoV-2 infection: A longitudinal prospective study nested to a population cohort. European Journal ofNeurology. 2021 Feb.
dc.source21. Asociación Colombiana de Infectología. Síndrome Post COVID-19: complicaciones tardías y rehabilitación. 2021 Apr 9
dc.sourceinstname:Universidad del Rosario
dc.sourcereponame:Repositorio Institucional EdocUR
dc.subjectCOVID-19
dc.subjectAfecciones posteriores al COVID-19
dc.subjectSecuelas
dc.subjectDesenlaces
dc.subjectVariantes
dc.subjectVacuna
dc.subjectCaracterización de la prevalencia de síntomas residuales del SARS-CoV-2
dc.titleSíntomas residuales posterior a la infección COVID-19 en un grupo pacientes de la ciudad de Bogotá durante el año 2020, análisis de una cohorte.
dc.typemasterThesis


Este ítem pertenece a la siguiente institución